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 The usefulness of detecting genomic instability in the form of microsatellite 
instability (MSI) has been examined in a number of cancers.  Squamous cell carcinoma 
(SCC) and adjacent normal and lichen sclerosis (LS) samples were taken from patients 
with radical vulvectomies.  Vulvar SCC samples were compared with adjacent normal 
samples using four oligonucleotide markers (BAT-25, BAT-26, D10S208 and D10S587) 
found to be informative with other carcinomas.  Using polymerase chain reaction 
techniques, 30 vulvar SCC DNA samples were examined for MSI.  BAT-26 displayed 
the highest level of MSI and was considered to be the most sensitive marker in studying 
vulvar SCC.   
There was not a statistically significant difference between adjacent normal and 
adjacent LS samples analyzed.  The level of MSI discovered in two of the four loci 
(BAT-26 and D10S208) were statistically significant when compared to adjacent normal 
samples and indicates a dysfunction in mismatch repair genes.  Genomic instability are 
pathways of carcinogenesis and is characterized by mismatch repair defects and MSI.  
Based on the high incidence of MSI in association with BAT-26, it appears that MSI has 




INTRODUCTION AND LITERATURE REVIEW 
 
1.1  Introduction 
Toxic waste and pollution has been a problem since the beginning of the 
industrial revolution.  Humans are exposed to a mixture of pollutants constantly 
throughout a normal lifetime.  The short-term and long-term effects of these exogenous 
chemical exposures are unknown or at best, not well understood.  Carcinogenesis and 
mutagenesis can result from these environmental exposures.  The number of individuals 
that have been diagnosed with cancer per capita each year has been increasing since the 
late seventies (Cancer Facts and Figures - 1997, American Cancer Society: Hoel et al., 
1992). 
Research is being conducted throughout the world in order to classify new and 
existing toxic chemicals.  Pesticides, cleaning products, and industrial chemicals are 
constantly being created or reformulated to increase their efficiency and function.  These 
changes in chemical properties also change the associated biological and toxicological 
properties.  We do not fully understand the biological and toxicological mechanisms and 
hazards of either these new or existing chemicals.  Until we have an understanding of 
these mechanisms, we cannot fully comprehend or mitigate the risk associated with toxic, 
mutagenic, or carcinogenic substances.  
The study of toxicology examines and tries to explain these environmental and 
human health problems.  Toxicology is the “study of adverse effects of chemicals on 
living organisms” (David and Curtis, 1995).  Genetic toxicology focuses on the 
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mutagenic effect of chemicals on DNA and RNA as well as the consequences of 
exposure to mutagens.  In genetic toxicology, we look at the mechanisms of mutagenesis, 
characteristics of mutagens and their human health effects.  Mutagens are chemicals and 
compounds that have the ability to alter DNA and can affect its fidelity of replication.  
Mutagenesis is important in studying genetic diseases, but it is also important in the study 
of carcinogenesis (George, 1995). 
1.2  Carcinogenesis 
Carcinogenesis is characterized as an accumulation of mutations in DNA that 
causes cellular dysfunction as well as uncontrolled growth.  These changes in function 
can lead to a decrease or failure of DNA repair mechanisms, failure of apoptosis 
(programmed cell death), and /or an increase in cell proliferation.  A carcinogen is an 
agent that causes or induces neoplasia (abnormal mass of relatively autonomous new 
growth of tissue), although a better definition would be “an agent whose administration to 
previously untreated animals leads to a statistically significant increased incidence of 
neoplasms in appropriate untreated animals” (Pitot, 1986). 
Recent studies have shown that tumor generation is performed in stages.  
Carcinogenesis can be the result one or more chemical, physical, biological and genetic 
insults to cellular structure and function (David and Curtis, 1995).  This multistage 
process can be broken down into three distinct steps: Initiation, Promotion, and 
Progression as show in table 1.1.  The first stage, initiation, results from one or more 
fixed mutations or genetic alterations.  Promotion is a reversible stage that involves the 
expression of the mutated genome mediated through promoter-receptor interactions.  
Progression is the final stage that is characterized by instability and tumor growth, and is 
 3 




Table 1.1 Characteristics of the stages of Carcinogenesis (modified from Pitot and 
Dragan, 1994). 
Initiation Promotion Progression 
Simple mutations Reversible both at the 
level of gene 
expression and at the 
cell level 
Irreversible genetic alteration 
in both cellular and genomic 
structures resulting from 
karyotypic instability. 
Point mutations in proto-
oncogenes and/or deletion 
or inhibition of tumor 
suppressor genes 
Inhibition of apoptotic 
pathways.  Increased 
cell proliferation 
Preneoplastic leasions and 
damage that can lead to 




Proto-oncogenes and tumor suppressor genes are critical targets in the initiation 
and promotion stage.  Alterations in these genes increase the risk of tumor development 
and promotion of neoplasia. Cancer is sometimes characterized as an accumulation of 
mutations during the initiation and promotion stages, with tumor development during the 
progression stage. 
1.3 Genomic Instability 
Cancer progression is a multi-stage process that involves an accumulation of 
mutations and an expansion of mutant lineages leading to incremental increases in tumor 
size, a transition from a benign to a malignant state, metastasis and disease pathology 
(Cahill et al., 1999; Lengauer et al., 1998).  A typical characteristic of cancer cells is the 
phenomenon of genetic instability (Cahill et al., 1999).   
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Genetic instability can be defined as an increase in the rate of mutation caused by 
corruptions in checkpoint genes that normally ensure faithful replication of the genome 
(Wodarz and Krakauer, 2001).  The relevance and role of genetic instability for cancer 
progression remains unclear.  The elevated rate of mutation effectively reduces the 
overall replication rate of the tumor cell population (Lengauer et al., 1998).  This is 
because a high mutation rate results in a reduced number of viable daughter cells. If the 
mutation rate is above a certain threshold, the tumor population can decrease.  Because of 
this, genetic instability can reduce the fitness of the tumor. 
During the cell cycle, the order of events is maintained by controls termed 
checkpoints.  Two checkpoints are sensitive to DNA damage, one that acts before mitosis 
and a second that acts before DNA replication (Weinert and Lydall, 1993). This is 
relevant to cancer because checkpoint mutants show genetic instability, and such 
instability is characteristic of many cancers (Wodarz and Krakauer, 2001). 
The loss of genomic stability in cancer cells is characterized by an accumulation 
of mutations.  One theory about cancer investigated in the early 1990’s by Bert 
Vogelstein is that when there is a loss genomic stability the cells will have a greater 
incidence of mutations (Fearon and Vogelstein, 1990).  In his Vogelgram, the progression 
of normal cells with genomic stability to carcinoma cells with a loss of genomic stability 
is detailed in figure 1.1 (Lengauer et al., 1998). 
1.4 Microsatellite Instability 
 The protein-coding regions of human DNA only account for about 3% of the 
human genome.  Most polymorphisms (DNA differences present in greater than 1% of 
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Figure 1.1: Vogelgram, Pathway to Cancer and Genomic Instability (Adapted Fearon and  
Vogelstein, 1990). 
 
p53 mutations are the most common mutation in human cancer (>50%).  
During the early and late cancer stages there is a total loss of genomic 
stability.  Deleted in Colorectal Carcinoma (DCC) and Mutation in Colorectal 
Carcinoma (MCC).  Instability with BAT-26 occurs in the early cancer stage 




























in the past, this area has been referred to as “junk” DNA.  The term “junk” DNA is now 
being considered a misnomer, these non-coding regions may play a vital role in protein 
synthesis and the normal functionality of the genome (Flam, 1994).  However, mutations 
in noncoding regions such as introns are being found that have multiple effects.  These 
effects include the disruption of splice site function, altering self-splicing RNA (the 
introns itself), an exon of another gene due to being encoded in the intron, or trans effects 
on other genes or distant DNA sequences. 
Non-coding regions of DNA may be located within genes (introns) or in between 
genes.  Normally, variations in these regions are functionally inconsequential, since the 
introns do not code for proteins.  Because introns are noncoding, there has developed 
tremendous genetic diversity in these regions.   Much of this non-coding DNA consists of 
highly repetitive segments of DNA with several iterations of specific sequences known as 
“DNA repeats”.  These repeated sequences can occur as a tandem array called Variable 
Number Tandem Repeats (VNTRs) and they are unique to each person and are the basis 
for the precise DNA fingerprinting (Edwards et al., 1992).   
Microsatellites are stretches of DNA in which a short motif (usually one to five 
nucleotides long) is repeated several times as a simple tandem repeat.    These short 
sequences are usually 15 to 300 nucleotides in length (Chapelle, 2003).  Microsatellites 
can be found in the human genome as a mononucleotide or dinucleotide (sometimes tri- 
or tetra-) repeat.  A single pair of polymerase chain reaction (PCR) oligonucleotide 
primers for specific microsatellite loci can produce variably sized DNA fragments 
depending upon the number of repeats. 
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The most common microsatellite found in humans is a dinucleotide repeat of 
cytosine and adenine, (CA)n.  Microsatellites are distributed unevenly throughout the 
human genome, and are frequently used as landmarks for gene mapping and 
identification (Chapelle, 2003).              
Many of these microsatellites are highly polymorphic (variable throughout human 
population) and instability of the microsatellite sites has been detected in a number of 
tumors.  Detecting microsatellite instability (MSI) involves comparing the length of 
microsatellite alleles amplified from tumor DNA with the corresponding allele in normal 
tissue from the same individual.  The addition or deletion of these novel microsatellite 
alleles in a tissue samples is called MSI.  
MSI is caused by a defective mismatch repair system.  As a consequence, errors 
that occur during replication of DNA cannot be repaired and lead to nucleotide mutations 
and alterations in the length of simple, repetitive microsatellite sequences (Slebos et al., 
2002).  MSI is regarded as an important phenotype of defective DNA mismatch repair 
and, consequently, as a marker of a high risk for cancer (Hartmann et al., 2002; Shin et 
al., 2002). 
It has been found that mutations in mismatch repair genes are responsib le for 
hereditary nonpolyposis colon cancer (HNPCC) (Loukola et al., 2001), and therefore 
HNPCC tumors frequently display genetic instability in the form of MSI (Goel et al., 
2003; Morifuji et al., 2002; Whitehall et al., 2002; Gryfe et al., 2000).  This was the first 
clue that a mismatch repair defect could be responsible for MSI in carcinomas.  The 
carcinoma tissue that was tested demonstrated new microsatellite alleles in tumor DNA 
compared to the associated nonneoplastic DNA.   
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MSI was discovered to be the result of germline mutations in the genes that 
encode the components of the DNA proofreading complex (Ichikawa et al., 2001; 
Morifuji et al., 2002).  It has been identified in a high percentage of tumors not only in 
patients with inherited defects in DNA mismatch repair enzymes, but also in a smaller 
but definite number of oral squamous cell carcinomas as well as other tumors such as 
endometrial carcinoma (Partridge et al., 2000).  The presence of additional microsatellite 
alleles in cancerous tissue, resulting from the inherent susceptibility of these areas to such 
alterations and from mutations in the DNA mismatch repair mechanism that would 
normally correct these errors, may be an important early event in carcinogenesis (Shin et 
al., 2002; Gryfe et al., 2000).   
Cancer arises as a result of the accumulation of genetic changes, which affect 
many chromosomes and genes.  Limited research has been done to show MSI in tissues 
with squamous cell carcinoma (SCC) and predisposing lesions such as lichen sclerosis 
(LS).  MSI has been seen in tissue associated with lung, colorectal, and other cancers.  
The focus of this project was to determine if human vulvar SCC and LS display genomic 
instability in the form of MSI. 
Despite numerous studies, the reported rates for MSI for each malignancy differ 
widely in the literature.  The discrepancies may stem from differences in the 
methodology used by each study, the assay techniques, and the specific reagents and 
enzymes.  Composites of methodologies (Materials and Methods) used in comparable 
studies were applied to the analysis of microsatellite instability in vulvar SCC in the 
present study.  Oligonucleotide primers were chosen based on previously published 
works dealing with MSI of the colon and oral SCC. 
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Oligonucleotide primer selection was based on literature citations with MSI.  Four 
microsatellite loci were chosen for this study based on previous literature reviews and 
cancers with comparative tissue types.  BAT-25, BAT-26, D10S208, and D10S587 were 
oligonucleotides used in the analysis of vulvar squamous cell carcinoma and associated 
tissues.  BAT-25 and BAT-26 are two mononucleotide markers considered highly 
informative in the study of MSI (Borland et al., 1998; Pyatt et al., 1999).  D10S208 and 
D10S587 were considered to be highly informative in the study of MSI in oral squamous 
cell carcinoma (Yshimitsu, 2002).  Since vulvar and oral squamous cell carcinoma are 
cancers of like tissues with comparative functions, it can be assumed that informative 
markers for oral SCC would be informative for vulvar SCC. 
Five microsatellite loci have been recommended by the international meeting of 
MSI investigators held by the National Cancer Institute in 1997 (Berg et al., 2000).  In 
1998, the International Workshop on Microsatellite Instability and RER (Replication 
Error Repair) Phenotypes in Cancer detection and Familial Predisposition published their 
approval of five microsatellite loci for the determination of MSI in tumors and associated 
tissues (Pyatt et al., 1999).  Of the recommended five-marker panel, three were 
dinucleotide microsatellites and two mononucleotide microsatellites, BAT-25 and BAT-
26.  Two of the four loci used in this study were BAT-25 and BAT-26.  Both are typical 
mononucleotide microsatellites, which contain a stretch of 25 and 26 adenines 
abbreviated (A)25 and (A)26, respectively. 
A study by Yamashita et al., in 2001, looked at MSI of chromosome 10 in 
association with oral SCC.  Sixteen microsatellite markers were considered for the 
analysis of MSI of chromosome 10.  Two of the sixteen markers were chosen to examine 
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MSI in this study.  D10S208 was selected because this microsatellite site exhibited the 
highest incidence of MSI and D10S587 demonstrated a high level of MSI and is 
associated with the Deleted in Malignant Brain Tumor 1(DMBT1) tumor suppressor gene 
(Yamashita et al., 2001). 
1.5  Mismatch Repair 
Human mismatch repair genes have the ability to repair both mismatched bases 
and insertion loop errors.  To repair mismatched bases, enzymatic mechanisms have to be 
able to distinguish which base is the correct one.  The GATC sequences in DNA are 
normally methylated (Me) at the 5 position of cytosine.  Immediately after DNA 
replication, the template strand has been methylated, but the newly synthesized strand is 
not yet methylated (Mitchell et al., 2002).  Because of this, the template strand and the 
new strand can be distinguished thus indicating the original or correct copy.  
During semiconservative DNA synthesis, a G-T mismatch arises in one of the 
sister DNA duplexes.  This is achieved by recognition of the transient lack of methylation 
of the newly synthesized strand before postreplicative DNA methylation takes place.  The 
nonmethylated daughter strand containing the incorrect base is enzymatically attacked by 
mismatch correction enzymes, and the mis- incorporated base is excised (Dunlop et al., 
1997).  Repair synthesis and daughter-strand methylation at GATC sequences restore the 
sister DNA duplexes to their native state (Figure 1.2). 
 Mismatch repair defects have been studied as a mechanism of carcinogenesis 











genes.  Recent in vitro evidence shows that cells with defective mismatch repair genes 
carry a high frequency of errors in microsatellite sequences and would be defined as MSI 
(Berg et al., 2000).  In affected carcinomas, the number of repeat units in the 
microsatellite site may either increase or decrease, although the composition of the unit 
itself is unaffected. 
1.6 Polymerase Chain Reaction (PCR) 
The Polymerase chain reaction (PCR) is a common method of creating copies of 
specific nucleic acid sequences.  Double stranded fragments or sections of DNA are 
replicated in a mixture of reagents and temperature cycles that are optimized for the 
sequence being amplified. This amplification of DNA is conducted in a series of cycles 
with each reaction cycle resulting in the formation of one copy from each DNA template.  
Each of the new strands and their template are then template for the next cycle.  The 
effect is a theoretical exponential growth rate of selected DNA fragments.  PCR requires 
a template DNA sample, a buffered solution of DNA polymerase, oligonucleotide 
primers for the template (forward primer) and coding strand (reverse primer), dATP, 
dCTP, dGTP, dTTP (deoxyribonucleic acid triphosphates/dNTPs), PCR reaction buffer, 
and magnesium ions (MgCl2) (Promega Corp., 1996). 
 Oligonucleotide primers are short oligonucleotides (containing about two dozen 
nucleotides) that are precisely complementary to the sequence at the 3' end of each strand 
of the DNA to be amplified.  These Oligonucleotides will anneal at their complimentary 
sequence and synthesis begins (as always 5' -> 3') using the original strand as the 
template.  During the extension step of PCR, the DNA polymerase adds dNTPs to the 3’ 
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carbon of the deoxyribose sugar moiety of the primer and then to the 3’ end of the 
developing fragment. 
 A PCR cycle is broken up into three distinct steps, denaturing, annealing, and 
extension as seen in figure 1.3.  Each step is conducted for between thirty seconds to one 
minute depending of the sequence being amplified.  In step 1, the DNA template is 
denatured using an extreme temperature of about 95ºC.  In step 2, the mixture is then 
cooled to an optimal annealing temperature as defined by the oligonucleotides; this can 
vary for each primer set.  In the third step, the chosen sequence is extended by a step wise 
addition of dNTPs by the DNA polymerase.  Thermus Aquaticus (Taq Polymerase) DNA 
polymerase is a heat stable polymerase used in PCR and is most efficient at 72ºC 
(Watson et al 1992). 
For the purposes of the present investigative work, oligonucleotide primer sets to 
detect MSI in SCC samples were selected based on current colorectal cancer studies and 
studies of oral SCC (Yshimitsu, 2002; Borland et al., 1998; Pyatt et al., 1999).  Four 
different sets of oligonucleotide primers for PCR were chosen to amplify different 
sequences in order to test for instability in multiple microsatellite sites (Table 1.2). 
 
 
            Table 1.2 Oligonucleotide location and Sequence 
 
Primer Location Microsatellite 
Repeat 
BAT-25 Intron 16, c-Kit protooncogene (T)25 
BAT-26 intron 5 hMSH2 tumor suppressor gene (A)26 
D10S208 10q (CA)24 




Polymerase Chain Reaction (PCR) 
 
5’                                              double stranded DNA                     3’ 
 
 
3’                   5’ 
Forward Primer       Reverse Primer 
    Primer Annealing (optimum Temp) 
5’                 3’ 
 
3’                 5’ 
 
Primer Extension (dNTP and Taq Polymerase) 
5’                 3’ 
 
3’                 5’ 
 
 
5’                 3’ 
 
Amplification of Target DNA 
3’                 5’ 
Denature DNA and Repeat Cycle 
5’         Forward Primer               3’ 
          Reverse Primer 
3’                 5’ 
5’          Forward Primer              3’ 
           Reverse Primer 
3’                 5’ 
4X Target DNA 
 
Figure 1.3: Polymerase Chain Reaction 
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1.7 Vulvar Squamous Cell Carcinoma (SCC) 
Vulvar Squamous Cell Carcinoma is a biologically and morphologically diverse 
disease consisting of tumors that differ in their morphological phenotypes and associated 
vulvar mucosal disorders (Pinto et al., 1999).  Vulvar SCC refers to an abnormal, 
cancerous growth in the external female genitalia, which includes the labia, the opening 
of the vagina, the clitoris, and the perineum.  SCC represents 90% of the vulvar cancer 
and occurs mainly in elderly women, but has been diagnosed in young women below the 
age of 20 (Carlson et al., 1998, Poulsen et al., 2003).  Women with this disease are more 
likely to recover if the cancer is diagnosed and treated early.  Although it can affect any 
part of the female genitalia, it usually affects the labia.   
Squamous cells are one of the main types of skin cells.  SCC often begins at the 
edges of the labia majora or labia minora or the area around the vagina.  This type of 
cancer is usually slow growing and may begin with a precancerous condition referred to 
as vulvar intraepithelial neoplasia, or dysplasia (Carlson et al., 1998).  These 
precancerous cells are present in the surface or epidermal layer of skin.  SCC in situ 
(high-grade vulvar intraepithelial lesion), the epithelium is thickened and it consists of 
atypical cells involving the entire thickness of the epidermis (Abeloff, Clinical Oncology 
2nd Ed., 2000). 
Vulvar SCC is most common in women over 50 years of age. Vulvar SCC has 
been associated with sexually transmitted diseases and the human paploma virus.  
Additional risk factors for vulvar cancer include having multiple sexual partners, 
immunodeficiency, cervical cancer, and the presence of chronic vaginal and vulvar 
inflammations (The Merck Manual of Diagnosis and Therapy, 1999).  Vulvar lichen 
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sclerosis is a known precancerous condition, characterized as chronic squamous cell 
dermatitis.   
1.8  Vulvar Lichen Sclerosis (LS) 
 
 Vulvar Lichen Sclerosis (LS) is a painful skin condition that typically affects the 
vulva and anus.  This condition is not contagious and is usually characterized as a chronic 
dermatosis of the vulva and surrounding tissues.  Vulvar lichen sclerosis is typically 
found in peri-menopausal women with a mean age of 54 years and begins as small white 
spots starting around the perineum (Wallace, 1971: Carlson et al., 1998; Powell and 
Wojnarowska, 1999).  The symptoms of lichen sclerosis are inflammation, swelling, 
thinning skin, burning, sores and lesions.  If not treated, lichen sclerosis can result in 
fusing of the skin, atrophy, and narrowing of the vagina. 
 It is not known what causes lichen sclerosis, but it has been found to be connected 
to thyroid disease, vitiligo, and autoimmune diseases (loss of skin pigment).  These 
findings show that there is a possibility that LS may be linked to genetic disorders.  LS 
predisposes the skin to cancer, as skin that is scarred by dermatosis is more likely to 
develop skin cancer.  About 1 in 20 women with untreated or misdiagnosed vulvar lichen 
sclerosis develops SCC (Carlson et al., 1998).  In a study of histologically confirmed LS 
by Carli et al., 1995, it was found that compared to an age-matched control group the 
cumulative risk of SCC was 14.8%. 
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CHAPTER 2 
MATERIAL AND METHODS 
 
2.1 Reagents   
 The Taq polymerase (AmpliTaq Gold) was purchased from Perkin-Elmer / 
Applied Biosystems (Foster City, CA).  The AmpliTaq Gold was used in all PCR 
reactions because of its stability.  Enzymes for end- labeling were purchased from New 
England Biolabs (beverly, MA).  The reagents and DNA samples were stored in a chest 
freezer at –20 ºC and were defrosted in an ice bath to ensure that they did not reach room 
temperature.   
Adinosine 5’-[γ-32P] Triphosphate Gamma was obtained from Amersham 
Bioscience Corporation (Arlington Heights, IL).  All radioactive material was stored and 
used in a room specific for the use of radioisotopes.  ATP [γ-32P] Gamma, radiolabeled 
primers, and radioactive PCR products were stored in a locked refrigerator. 
2.2  Tissue Samples 
 Thirty SCC, fifteen adjacent LS, and ten tumor adjacent normal tissue samples 
were isolated and extracted for analysis.  The genomic DNA was isolated from vulvar 
tissue samples obtained and histologically categorized as SCC, LS, or normal by Dr. 
Andrew Carlson (Albany Medical College), and shipped to LSU individually packaged 
and frozen.  The vulvar tissue samples were kept in a freezer at –80ºC until the genomic 
DNA could be extracted and isolated.  The remaining tissue sample was then repackaged 
and stored in the freezer at –80ºC.  
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 Over a hundred vulvar tissue specimens were obtained from radical vulvectomy 
patients and supplied to our laboratory for analyses.  Dr. Carlson has completed 
pathological and clinical data on each specimen received.  The tissue samples were split 
three ways, one was frozen at –80ºC, the second was fixed in formalin for histologic and 
eosin examination as well as quantitative and qualitative analysis of multiple 
immunohistochemical and fluorescent in situ hybridization (FISH) markers of 
cytogenetic and neoplastic progression.  The third portion was submitted to short-term 
culture for cytogenetic karyotyping.  The second and third samples have been or will be 
analyzed by Dr. Carlson’s laboratory. 
2.3  Extraction and Purification 
 Two different protocols were followed in order to extract and purify the genomic 
DNA.  The first method used a standard phenol and chloroform extraction with 
concentration of DNA by ethanol precipitation (Ausubel, et al., 1999).  The detailed 
method for the phenol and chloroform extraction and ethanol precipitation can be found 
in appendix A and B, respectively.  The second method was the use of the Qiagen Kit 
(Qiagen Inc., Chatsworth, CA) for the extraction and purification of genomic DNA from 
human tissue.  
  2.4  Spectrophotometric Determination of DNA Concentration 
 The DNA products from these extraction and isolation protocols were analyzed 
for purity and output from their optical density using a Beckman DU-64 
Spectrophotometer.  The bases of DNA molecules absorb ultraviolet (UV) light at a 
maximum absorbance wavelength of 260 nm.  Because the base pairs are able to absorb 
UV light at A260 (absorbance at 260 nm), the total concentration of DNA in the solution 
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can be measured.  An A260 (also known as optical density) of 1.0 equates to 50µg/ml of 
double stranded DNA in a 1 cm spectophotometric beam path.  This spectrophotometric 
determination of the concentration can be done if the solution has little or no protein 
contamination. 
 Proteins and RNA absorb UV light at a wavelength of A280, and so the reading at 
this wavelength is a measure of protein and RNA contamination.  If the concentration is 
pure, then the ratio of A260:A280 will be theoretically 1.95.  When the ratio  is 
significantly less than 1.95, the sample is too contaminated with either proteins or RNA 
to use the spectrophotometric method.  In this case, a concentration standard method can 
be employed to estimate the concentration of DNA in a solution by loading a known 
volume of the sample into an agarose gel, along with an identical volume of DNA with a 
known concentration. 
2.5  Polmerase Chain Reaction (PCR) Amplicfication 
Each primer sequence was analyzed using software for the Macintosh called 
Oglio 5.0v analysis software (National Biosciences, Inc., Plymouth, MN).  The software 
helped to estimate the proper annealing temperature for each primer and the probability 
that it might anneal to itself during the PCR reaction forming dimers. These primer 
dimers can reduce the efficiency of the PCR reaction and decrease total amplification of 
the targeted sequence. 
The PCR reactions were standardized on a 9700 Thermal-Cycler by Perkin-
Elmer/ Applied Biosystems (Foster City, CA).  Each reaction contained 200 ng of DNA, 
1 unit of AmpliTaq Gold, 1.5 mM MgCl2, 200 mM dNTPs, 1mM of each PCR primer, 1 
µl of end labeled forward primer (Appendix C) and 1X PCR buffer in a total volume of 
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25 µl.  The DNA was denatured at 95ºC for 7 minutes then amplification was carried out 
for 35 cycles of 95ºC for 1 minute, 1 minute at 55ºC (BAT-26 and D10S208) and 58 ºC 
(BAT-25 and D10S587), and 72ºC extension for 1 minute, followed by a 10 minute 720C 
extension (Appendix D). 
2.6  Polyacrylamide Gel Electrophoresis 
 The 32p labeled PCR amplified products were run on a 7M urea, 5% denaturing 
polyacrylamide sequencing gel (Appendix E).  The gel was vacuum dried on a Model 
583 gel dryer from Bio-Rad at 65ºC for 20 minutes and then allowed to cool for 10 
minutes.  The gel was transferred to an exposure cassette with intensifying screens and 
placed in the –80ºC freezer for 4-24 hours depending on the signal strength of the 
products. 
2.7  PCR Oligonucleotide Selection 
 PCR primers were selected based on literature citations with MSI.  BAT-25, 
BAT-26, D10S208, and D10S587 were the four loci chosen for the analysis of MSI.  
BAT-25 and BAT-26 were recommended by a reference panel for detecting high 
frequency MSI in colorectal cancer (Borland et al., 1998) and D10S208 and D10S587 
were selected from a paper on oral squamous cell carcinoma by Yshimitsu, 2002.   
PCR primers D10S208 and D10S587 were sited as being associated with oral 
squamous cell carcinoma and are relevant in studying vulvar SCC because of the 
similarity in cell type and tissue function.  Both of these microsatellite markers are 
dinucleotide repeats of cytosine and adinosine (CAn).   D10S587 is associated with the 
DMBT1 tumor suppressor gene and D10S208 was found to be the most informative 
marker in oral squamous cell carcinoma. 
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 Incidence of primer dimers and loops were analyzed using Oligo v5.0 Primer 
Analysis software (National Biosciences, inc., Plymouth, MN).  The PCR primers were 
purchased from BioServe Biotechnologies, Ltd (Laurel, MD).  The sequences of the PCR 
primers and experimentally determined optimal annealing temperatures for primer sets 
are displayed in Table 2.1.  
 







BAT-25 121-126 58ºC 5’-TCG CCT CCA AGA ATG TAA GT-3’ 
5’-TCT GCA TTT TAA CTA TGG CTC-3’ 
BAT-26 125 55ºC 5’-TGA CTA CTT TTG ACT TCA GCC-3’ 
5’-AAC CAT TCA ACA TTT TTA ACC C-3’ 
D10S208 181 55ºC 5’-AAG TGA CTG TTT TGG GGG AG-3’ 
5’-CCC ACA ACT CAA TAA ACT CAA ACT C-3’ 
D10S587 179 58ºC 5’- CCC AGA TTC ATG GCT TTC-3’ 
5’- TTC TGC TGA CAC GGG C-3’ 
 
 
2.8  BAT-25 and BAT-26 
MSI status was determined by screening the polyadenosine sequence, BAT-26, 
which has proved 99.4% efficient at detecting MSI-associated cancer.  The BAT-25 and 
BAT-26 loci are both mononucleotide repeats containing a 25-repeat terosine tract (poly 
T) and a 26-repeat deoxyadenine tract (poly A), respectively.  BAT-26 is a highly 
sensitive mononucleotide repeat; located within the fifth intron of the hMSH2 (human 
MutS homologue) gene and is a specific indicator of generalized MSI as evident in 
human cancers.   
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 BAT-25 and BAT-26 were selected for this study based on markers picked by two 
conferences on the study of MSI.  Both microsatellite loci are mononucleotide repeats 
and are considered to be sensitive markers for MSI (Loukola et al., 2001).  The BAT-25 
locus contains a 25-repeat thymine tract, (T)25, located within intron 16 of the c-Kit proto-
oncogene, assigned to 4q12  (Figure 2.1) (Morifuji et al., 2002; Ichikawa et al., 2001; 
Pyatt et al., 1999).  The c-Kit gene is important for the protein KIT receptor and proper 
cell proliferation.  When damaged, the KIT receptor can be continuously activated, which 
caused the receptor to signal the cell to divide, without the proper stimulus (London et al., 
1996).  
 The BAT-26 locus contains a 26-repeat adinosine tract, (A)26, located within 
intron five of the hMSH2 (human MutS homologue) tumor suppressor gene (Figure 2.2) 
(Pyatt et al., 1999; Loukola et al., 2001; Shin et al., 2002; Morifuji et al., 2002).  The 
hMSH2 tumor suppressor gene is a mismatch repair gene necessary for maintenance of 
DNA fidelity. Studies of MSI have been focused on defective mismatch repair genes in 
the pathogenesis of malignant carcinoma.  Cells with defective mismatch repair 
mechanisms can not correct genetic errors that occur during cellular replication, e.g., 
point mutations, deletions, insertions and strand slippage.  Thus, the fidelity of DNA 
replication is reduced.  
Loss of control over cell growth and proliferation may occur when there are 
mutations of proto-oncogenes and tumor suppressor genes.  Cells with mutated or deleted 
mismatch repair genes are not able to repair replication errors during DNA replication, 
microsatellites are particularly prone to replication errors, and so MSI is the hallmark of  
 
 23 
Homo Sapiens c-Kit proto-oncogene, intron 16 sequence 
 
GenBank U63834 
Product Length: 125bp 
 
 
80101 CCTCTCTTCC TCACAGGCTC ATACATAGAA AGAGATGTGA CTCCCGCCAT CATGGAGGAT 
      GGAGAGAAGG AGTGTCCGAG TATGTATCTT TCTCTACACT GAGGGCGGTA GTACCTCCTA 
 
     
80161 GACGAGTTGG CCCTAGACTT AGAAGACTTG CTGAGCTTTT CTTACCAGGT GGCAAAGGGC 
 CTGCTCAACC GGGATCTGAA TCTTCTGAAC GACTCGAAAA GAATGGTCCA CCGTTTCCCG 
 
      à BAT-25 F 20mer 62ºC ß  
80221 ATGGCTTTCC TCGCCTCCAA GAATGTAAGT GGGAGTGATT CTCTAAAGAG TTTTGTGTTT 
 TACCGAAAGG AGCGGAGGTT CTTACATTCA CCCTCACTAA GAGATTTCTC AAAACACAAA 
 
      à     Microsatellite Site    ß 
80281 TGTTTTTTTG ATTTTTTTTT TTTTTTTTTT TTTTTTTGAG AACAGAGCAT TTTAGAGCCA 
 ACAAAAAAAC TAAAAAAAAA AAAAAAAAAA AAAAAAACTC TTGTCTCGTA AAATCTCGGT 
              à 
 
80341 TAGTTAAAAT GCAGAATGTC ATTTTGAAGT GTGGTAACCA AAAGCAGAGG AAATTTAGTT 
 ATCAATTTTA CGTCTTACAG TAAAACTTCA CACCATTGGT TTTCGTCTCC TTTAAATCAA 
 BAT-25 R 21mer     60ºC      ß 
 
80401 TCTTCATGTT CCAACTGCTG TCTCTTTGGA ATTCCTGTTC TAATTTATAA GCTGTAAAGT 
 AGAAGTACAA GGTTGACGAC AGAGAAACCT TAAGGACAAG ATTAAATATT CGACATTTCA 
 
 
80461 ACAAGCCTGT CTAAATGAGT TTTTCTATGA ATATTCTTTT ATATGCAGTG AAATTCTTTT 
 
80581 AAAACTTTTG GCTTTTAGGA TATAGGATAT GTTCCTAGAG AACAGAATCA TTTTATCAGT 
 
80641 TGAAGTTAGA TCCAAATATT ATATGTGTGG CTTATGAAGT GTCAGGAAAT AAGGGGTCAG 
 
80701 AGGGAGTAAT AAACACTTGG GAGAAGGTTA GGAATGGAAA GAATGATGGA ACCAAAACAA 
 
80761 GGAGCATGGT CTGTGGAAGG GTGAAAGGAG TTCCTTAGGA AGTAAGATTA ACCGAACAGA 
 
80821 ATGAGTTACC AGTCCTACCC TTAAATGTCA TGGGTGACAT TTCCCAACAA TTACCAAACT 
 
80881 AAGAAAGGAT ATAAGATGGC TGAAATAAAG ACCTTCTTCC GTGTGTCCTT GGGAGATGTC 
 
80941 AGATTGAATT TGCAAAGGCA TATTAGGAAC TCTGTGAAAG GACATTCAAA GAGATGCATG 
 
81001 CAAAATGAAT TTTCAGTTTA AACAATATGA TATGACTATT TCTTATGTAT TTCCCTATGA 
 
81061 ATGAAAGCAG TCCTGAGAAG AAAACAGCAT TTATTAGAAT TGCTTTTAAA AGAGATTATA 
 
81121 ATAATTAGAC TCTTGATTAT GCGAACATCA TTCAAGGCGT ACTTTTGATT TTTATTTTTG 
 
 






Homo Sapiens MSH2 tumor suppressor gene, introns 5 Sequence 
 
GenBank U63834 




80001 CCAGTGGTAT AGAAATCTTC GATTTTTAAA TTCTTAATTT TAGGTTGCAG TTTCATCACT 




80061 GTCTGCGGTA ATCAAGTTTT TAGAACTCTT ATCAGATGAT TCCAACTTTG GACAGTTTGA 
      CAGACGCCAT TAGTTCAAAA ATCTTGAGAA TAGTCTACTA AGGTTGAAAC CTGTCAAACT 
 
 
     à  BAT-26 F 21mer  60ºC   ß 
80121 ACTGACTACT TTTGACTTCA GCCAGTATAT GAAATTGGAT ATTGCAGCAG TCAGAGCCCT 
      TGACTGATGA AAACTGAAGT CGGTCATATA CTTTAACCTA TAACGTCGTC AGTCTCGGGA 
 
 
         à  Microsatellite Site      ß   
80181 TAACCTTTTT CAGGTAAAAA AAAAAAAAAA AAAAAAAAAA AGGGTTAAAA ATGTTGATTG 
      ATTGGAAAAA GTCCATTTTT TTTTTTTTTT TTTTTTTTTT TCCCAATTTT TACAACTAAC 
            à  BAT-26 R 22mer 62ºC    
 
 
80241 GTTAANNNNN NNNGACAGAT AGTGAAGAAG GCTTAGAAAG GAGCTAAAAG AGTTCGACAT 
      CAATTNNNNN NNNCTGTCTA TCACTTCTTC CGAATCTTTC CTCGATTTTC TCAAGCTGTA 
    ß 
 
 
80301 CAATATTAGA CAAG 
      GTTATAATCT GTTC 
 









inactivated mismatch repair genes, which can lead to increased risk of oncogenesis (Shin 
et al., 2002; Morifuji et al., 2002). 
Because of the quasimonomorphic (low occurrence of polymorphisms) profile of 
both loci, BAT-25 and BAT-26 have proven very useful for the identification of MSI 
(Pyatt et al., 1999).  The shortened and unstable alleles can easily be differentiated from 
alleles of normal size. 
2.9  D10S208 and D10S587 
 The deleted in malignant brain tumors 1 (DMBT1) gene is located on 10q25.3-
26.1 (Sasaki et al., 2002; ) and the deletion or loss of expression of the DMBT1 gene has 
been reported in association with brain, esophagus, stomach, colon and lung cancers 
(Yamashita et al., 2001).  D10S2587 is a dinucleotide composed of 20 repeats of 
adenosine and cystein, (AC)20 (Figue 2.3),  microsatellite site contained within the 
DMBT1 tumor suppressor gene.  This locus was chosen because of the connection 
between the DMBT1 tumor suppressor gene and oral SCC (Yamashita et al., 2001).  Oral 
and vulvar SCC are cancers of related tissue types, both are mucosa tissue.   
In a study by Yasuhiro Yamashita in 2001, 16 microsatellite sites located on 
chromosome 10 were investigated to see the correlation between oral SCC and MSI.  Of 
the 16 loci chosen for the study, D10S208 displayed the highest degree of MSI.  
D10S208 is a dinucleotide made up of 24 repeats of cystein and adenosine, (CA)24 
(Figure 2.4).  Although it is not associated with a tumor suppressor gene or proto-





Homo Sapiens (D10S587) DNA segment containing (CA) repeat, Associated with 








   à D10S587 F 17mer 60ºC ß 
    1 AGCTCATTGA GAAGAATAAC AGGCCCAGAT TCATGGCTTT CACTCAGCCC TTCCTTTCTT 




              à                         Microsatellite Site                    ß 
   61 TGGGTTGAAA CACACACACA CACACACACA CACACACACA CACACACACT GTCTTACCTT 





  121 CTGTGAGTGG GAGGGTGTCA GTGCCTCTTC AGATGTCTGC TTTTTGATAT TAACCACTTG 
 GACACTCACC CTCCCACAGT CACGGAGAAG TCTACAGACG AAAAACTATA ATTGGTGAAC 
 
 
     
  181 CTGGCCCGTG TCAGCAGAAA GGCTCTGTAT AGATGTCGTT TAGCGGGAAT TCCTAAAGCC 
 GACCGGGCAC AGTCGTCTTT CCGAGACATA TCTACAGCAA ATCGCCCTTA AGGATTTCGG 
    à  D10S587 R 16mer  ß 
                             60ºC              
 
 
  241 CTCCCCTCCC TCTAAGGCCT CCAGAGACCA CCCTACCTTC TAGGTCACAA ATGAGATGTC 





  301 TTCTAGGTCA CAAATGAGAT GTCTGAACCT TTATACCTGC TGGTCTCCAG CT 
 AAGATCCAGT GTTTACTCTA CAGACTTGGA AATATGGACG ACCAGAGGTC GA 
 
 
 Figure 2.3: Sequence and Binding Site of the D10S587 Loci 








Homo Sapiens (D10S208) DNA segment containing (CA) repeat, Sequence 
 
 





                                      à  D10S208 F 20Mer 58ºC  ß        
  1  AGCTATATTT GAGACCTTTN AGGTGACTGT TTTGGGGGAG GGGCAATATT TTCAAATTCT 




               à Microsatellite Site 24 CA   
 61  GAAATTTCTT ATTTAGAAAT AATTATTGGA TCTCACACAC ACACACACAC ACACACACAC 




     Repeat         ß 
121  ACACACACAC ACACACACAC AAACTTACCT GTGGTTCTTG TTCTCTGAAG GACATNCAGT 





181  ANTTGAAAAC ATCCCCACAC TCTTGGGTAC ATTCTCCTAA GTGTG 
TNAACTTTTG TAGGGGTGTG AGAACCCATG TAAGAGGATT CACAC 









RESULTS AND DISSCUSSION 
 
To study the association of MSI with vulvar SCC and adjacent vulvar LS, the 
presence and frequency, if applicable, of additions or deletions in each of the 
microsatellite loci were tested.  Some of the DNA samples analyzed could not be 
amplified by all of the microsatellite markers, these samples were considered to be non-
informative (NI) and were not considered in calculating the percent instability.  NI 
samples were analyzed a second time to ensure that the results were not due to 
procedural failure.  SCC samples displayed a greater frequency of NI than the adjacent 
normal and adjacent LS samples, which displayed a comparative frequency.   
3.1 General Results 
In this study, vulvar SCC, adjacent LS and adjacent normal tissue samples were 
examined using four microsatellite loci (BAT-25, BAT-26, D10S208 and D10S587) in 
order to establish that these markers were informative in studying vulvar SCC.  The 
association with MSI is an important marker of genetic instability that characterizes 
cancers with replication errors and nonfunctional mismatch repair genes. Representative 
samples that tested positive (+) for MSI were analyzed a second time to ensure 
reproducibility.  Adjacent normal tissue samples as well as blanks were used in each 
PCR reaction as positive and negative controls and for comparison to establish the 
presence or the absence of MSI. 
It was found that BAT-26 was the most informative marker for MSI and was 
found to be significantly different than the adjacent normal tissue tested (p=0.0013).   
D10S208 was considered to be informative and displayed a significant difference in 
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MSI when compared to the adjacent normal tissue tested (p=0.009).  The adjacent 
normal and adjacent LS tissue tested indicated no significant difference in MSI and was 
considered to be microsatellite stable (MSS) or to have a low occurrence of MSI (MSI-
L), with only two adjacent LS specimens considered to have a high occurrence of MSI 
(MSI-H).The results of all of the tests for MSI conducted in this study are found on 
Table 3.1. 
 
Table 3.1: Results from MSI analysis of all tissue types. 
Vulvar Specimens for Microsatellite Instability 
Specimen Identifier BAT-25 BAT-26 D10S208 D10S587 Stability 
CW 3-3 SCC - + NI - MSI L 
CW 5-1 SCC NI + + - MSI H 
CW 12-4 SCC - - - + MSI L 
CW 16-2 SCC - - + NI MSI L 
CW 16-3 N - - - NI MSS 
CW 17-1 SCC - - - - MSS 
CW 17-5 N - - - - MSS 
CW 17-6 LS - - + NI MSI-L 
CW 18-1 SCC - - - - MSS 
CW 18-5 N - - - - MSS 
CW 19-1 SCC - - - - MSS 
CW 19-2 SCC NI - NI NI NI 
CW 21-2 LS - - - - MSS 
CW 23-1 SCC - + - NI MSI L 
CW 23-3 N - - - - MSS 
CW 24-1 SCC - + - NI MSI L 
CW 25-1 SCC - + - NI MSI L 
CW 25-4 LS - - - - MSS 
CW 26-2 SCC + + + + MSI H 
CW 28-1 SCC - + - - MSI L 
CW 28-4 LS - - - - MSS 
CW 29-1 SCC - NI + + MSI H 
CW 29-3 N - - - - MSS 
CW 29-5 LS - - - - MSS 
CW 29-6 SCC - + - + MSI H 
CW 30-6 LS - NI - - MSS 
CW 35-3 SCC NI - NI NI NI 
CW 39-1 N - - - - MSS 
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(Table 3.1 Continued) 
Specimen Identifier BAT-25 BAT-26 D10S208 D10S587 Stability 
CW 39-2 SCC - + - + MSI H 
CW 39-3 LS + + + - MSI H 
CW 40-1 SCC + - - - MSI L 
CW 40-4 N - - - - MSS 
CW 40-5 LS - - - - MSS 
CW 41-1 SCC - - + - MSI L 
CW 41-8 SCC - + - - MSI L 
CW 43-1 SCC - - + + MSI H 
CW 44-1 N - + - - MSI L 
CW 44-2 SCC - + + - MSI H 
CW 44-4 LS - + - + MSI H 
CW 45-4 N - NI - - MSS 
CW 46-6 LS - - - - MSS 
CW 47-2 SCC - - + - MSI L 
CW 47-3 LS - NI - - MSS 
CW 49-1 SCC - NI - - MSS 
CW 49-4 LS - - - - MSS 
CW 49-6 LS - - - - MSS 
CW 49-7 N + - - - MSI L 
CW 50-1 SCC - + + - MSI H 
CW 50-5 LS - - - - MSS 
CW 52-2 N - NI - - MSS 
CW 57-1 SCC NI + - - MSI L 
CW 61-2 LS - - - - MSS 
CW 61-6 SCC - + + - MSI H 
CW 63-1 SCC + + + - MSI H 
CW 64-3 SCC - + - - MSI L 
CW 70-1 LS - - - - MSS 
CW 70-3 SCC - - - - MSS 
CW 70-5 LS - - - - MSS 
CW 70-7 N - NI - - MSS 
CW 73-1 N - - - + MSI-L 
CW 80-2 SCC NI + - - MSI L 
CW 91-5 LS - - - - MSS 
CW 97-1 SCC - - - - MSS 
 Informative Cases MSI + % MSI SCC % MSI LS % MSI Normal 
BAT-25 27.0 3.0 11.1 5.6 7.7 
BAT-26 30.0 17.0 56.7 12.5 10.0 
D10S208 30.0 11.0 37.9 11.1 0.0 
D10S587 26.0 6.0 23.1 5.9 8.3 
+  Positive for MSI 
-  Negative for MSI                           NI Non Informative with specified marker 
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3.2 BAT-25 
 The BAT-25 locus has been shown to be a sensitive marker of MSI, and is 
characterized by a shortening or lengthening in the size of the mononucleotide repeat in 
tumor DNA and is shown on an autoradiograph as a banding of alleles.  MSS tumor, 
adjacent lichen sclerosis, or adjacent normal tissues exhibit little or no polymorphic 
variation in the size of the poly (T) tracts.  This fact is useful in the analysis of MSI, 
allowing the use non-associated normal DNA samples.  Because of these 
characteristics, shortened, unstable alleles can easily be differentiated from alleles of 
normal size.   
A total of thirty-two primary tumors and thirteen adjacent normal tissues from 
patients with SCC were screened for MSI using BAT-25, a quasimonomorphic (low 
occurance of variation in population) marker used in the study of HNPCC (Morifuji et 
al., 2002; Loukola et al., 2001; Gryfe et al., 2000).  The frequency of MSI was studied 
in sixteen associated lichen sclerosis tissue samples in order to study the possibility of 
progression from normal to tumor.  Progression of MSI was studied using five 
individual cases containing at least on sample from each category, normal, LS, and SCC 
tissue.  
Of the thirty-two SCC samples analyzed, three samples were characterized as 
positive (+) for MSI (Table 3.2).  Twelve percent of the SCC samples showed MSI and 
was not found to be significantly different than the MSI in normal tissue (p=1.00).  This 
would indicate that this locus was not a sensitive marker for vulvar SCC.  Five of the 
thirty-two SCC tissue samples were considered non- informative and could not be 
characterized as either MSI or MSS.   
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The corresponding adjacent normal tissue samples were negative (-) for MSI in 
all but one of the eleven cases that were analyzed.  The seventeen of the eighteen 
samples of adjacent LS tissue with matching SCC cases were also negative (-) for MSI.  
Representative examples of the analysis of MSI with BAT-25 are illustrated in figure 
3.1.  
 
Table 3.2 Assessment of SCC tissue for MSI with BAT-25 
Specimen Identifier BAT-25 Specimen Identifier BAT-25 
CW 3-3 SCC - CW 39-2 SCC - 
CW 5-1 SCC NI CW 40-1 SCC + 
CW 12-4 SCC - CW 41-1 SCC - 
CW 16-2 SCC - CW 41-8 SCC - 
CW 17-1 SCC - CW 43-1 SCC - 
CW 18-1 SCC - CW 44-2 SCC - 
CW 19-1 SCC - CW 47-2 SCC - 
CW 19-2 SCC NI CW 49-1 SCC - 
CW 23-1 SCC - CW 50-1 SCC - 
CW 24-1 SCC - CW 57-1 SCC NI 
CW 25-1 SCC - CW 61-6 SCC - 
CW 26-2 SCC + CW 63-1 SCC + 
CW 28-1 SCC - CW 64-3 SCC - 
CW 29-1 SCC - CW 70-3 SCC - 
CW 29-6 SCC - CW 80-2 SCC NI 
CW 35-3 SCC NI CW 97-1 SCC - 
 BAT-25 Informative 
Cases 
MSI + % MSI  
SCC 27.0 3.0 11.1 
LS 18.0 1.0 5.6 
N 13.0 1.0 7.7 
 +  Positive for MSI 
 -  Negative for MSI 







    1            2           3           4 5 6 7 8 9 10 
 
Figure 3.1: Representative samples of the analysis of MSI with BAT-25 
 
Audioradiograph of MSI test.  Lane 4 is a blank and was the negative control in this 
analysis with water instead of the DNA template.  Lanes 1 and 2 are positive controls of 
normal DNA template for comparison to SSC tissue.  Lane 9 was positive for MSI and 




The BAT-26 locus has demonstrated in previous cancer studies that it can be an 
extremely sensitive marker for a variety of cancers.  MSI in this allele is mainly 
characterized by a deletion of between five and fifteen bases when compared to normal 
tissue (Morifuji, 2002).  The BAT-26 locus is a quasimonomorphic, poly (A) repeat of 
26 adenosines that has been used in numerous studies of MSI and is associated with 
dissimilar tumors and cancerous tissues. 
SCC, adjacent lichen sclerosis, and adjacent normal tissues were analyzed and 
those that displayed an alteration in the size of the allele were considered to be positive 
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(+) for MSI.  Thirty-one SCC tissue samples were tested using BAT-26, and thirty 
samples were considered to be informative.  Seventeen (56.7%) of the thirty informative 
cases tested positive (+) for MSI as shown in Table 3.2.   Since seventeen cases (56.7%) 
exhibited an allelic shift, the BAT-26 locus was considered a highly informative marker 
with respect to vulvar SCC.  The high percentage of MSI found in BAT-26 suggests a 
lack of expression of the mismatch repair genes in the SCC tissue, specifically the 
hMSH2 tumor suppressor gene. 
 
    Table 3.3 Assessment of SCC tissue for MSI with BAT-26 
Specimen Identifier BAT-26 Specimen Identifier BAT-26 
CW 3-3 SCC + CW 39-2 SCC + 
CW 5-1 SCC + CW 40-1 SCC - 
CW 12-4 SCC - CW 41-1 SCC - 
CW 16-2 SCC - CW 41-8 SCC + 
CW 17-1 SCC - CW 43-1 SCC - 
CW 18-1 SCC - CW 44-2 SCC + 
CW 19-1 SCC - CW 47-2 SCC - 
CW 19-2 SCC - CW 49-1 SCC NI 
CW 23-1 SCC + CW 50-1 SCC + 
CW 24-1 SCC + CW 57-1 SCC + 
CW 25-1 SCC + CW 61-6 SCC + 
CW 26-2 SCC + CW 63-1 SCC + 
CW 28-1 SCC + CW 64-3 SCC + 
CW 29-1 SCC NI CW 70-3 SCC - 
CW 29-6 SCC + CW 80-2 SCC + 
CW 35-3 SCC - CW 97-1 SCC - 
BAT-26 Informative 
Cases 
MSI + % MSI 
SCC 30.0 17.0 56.7 
LS 16.0 2.0 12.5 
N 10.0 1.0 10.0 
 +  Positive for MSI 
  -  Negative for MSI 




Aberrant fragments from the PCR amplification were detected in one (10.0%) 
sample out of the ten adjacent normal tissue samples tested.  The adjacent lichen 
sclerosis samples studied showed an increase in MSI, but were not significantly 
different than normal tissue.  The MSI detected in the SCC tissue using the BAT-26 
locus was found to be significantly different from the adjacent normal tissue samples 
tested (p=0.0013).  This relationship follows the dogma that from normal to LS to SCC 
is a progression characterized by increased instability in this microsatellite locus.  
Representative examples of the analysis of MSI in the three tissue types are illustrated 
in figure 3.2. 
 
 
    1            2       3         4          5        6       7             8         9             10     11         12 
Figure 3.2: Representative samples of the analysis of MSI with BAT-26 
 
Audioradiograph of MSI test.  Lane 3 is a blank and was the negative control in this 
analysis with water instead of DNA template.  Lanes 6 and 7 are positive controls of 
normal DNA template for comparison to SSC tissue.  Lane 1, 2, 5, 10, and 11 were 
positive for MSI and is characterized by a deletion of bases and the separation of alleles.  
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3.4  D10S208 
 D10S208 is a dinucleotide microsatellite site consisting of 24 cytosine and 
adenosine, (CA)24, repeats located on chromosome 10 (10q).  Although this locus is not 
associated with a tumor suppressor gene or proto-oncogene, it was considered to be a 
highly informative marker by Yasuhiro Yamashita (2001) for MSI in human oral 
squamous cell carcinoma.  Since the oral and vulvar tissues are both mucosal tissue  and 
similar in function, D10S208 was considered for the analysis of vulvar SCC in this 
study.    
Out of the thirty-two primary tumor samples analyzed, thirty samples were 
considered informative.  MSI was found in eleven (37.9%) of the thirty SCC samples 
tested (Table 3.4).  The high percentage of instability of the D10S208 locus in 
association with the tumor tissue samples analyzed is considered to be evidence that this 
microsatellite marker can be considered informative with respect to vulvar SCC. 
The level of MSI detected in the SCC tissue using the D10S208 locus was found 
to be significantly different from the normal and lichen sclerosis samples (p=0.009).  
Thirteen adjacent normal and eighteen adjacent lichen sclerosis tissue samples were 
tested for MSI.  Two adjacent LS samples tested positive (+) for MSI, sixteen adjacent 
LS and 13 adjacent normal samples tested negative for MSI.  Representative examples 
of the analysis of MSI in the three tissue types are illustrated in figure 3.3.   
3.5  D10S587 
 D10S587 is a dinucleotide microsatellite site consisting of 20 adenosine and, 
cytosine (AC)20, repeats located on chromosome 10 (10q25.3-26.1) (Sasaki et al., 
2002).  This highly polymorphic marker is mapped around the DMBT1 tumor 
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suppressor gene.  Because of the association with the DMBT1 gene and oral SCC, the 
D10S587 was considered to have potential in this study of vulvar SCC. 
 
Table 3.4 Assessment of MSI with D10S208 
Specimen Identifier D10S208 Specimen Identifier D10S208 
CW 3-3 SCC NI CW 39-2 SCC - 
CW 5-1 SCC + CW 40-1 SCC - 
CW 12-4 SCC - CW 41-1 SCC + 
CW 16-2 SCC + CW 41-8 SCC - 
CW 17-1 SCC - CW 43-1 SCC + 
CW 18-1 SCC - CW 44-2 SCC + 
CW 19-1 SCC - CW 47-2 SCC + 
CW 19-2 SCC - CW 49-1 SCC - 
CW 23-1 SCC - CW 50-1 SCC + 
CW 24-1 SCC - CW 57-1 SCC - 
CW 25-1 SCC - CW 61-6 SCC + 
CW 26-2 SCC + CW 63-1 SCC + 
CW 28-1 SCC - CW 64-3 SCC - 
CW 29-1 SCC + CW 70-3 SCC - 
CW 29-6 SCC - CW 80-2 SCC - 




Cases MSI + % MSI 
SCC 30.0 11.0 37.9 
LS 18.0 2.0 11.1 
N 13.0 0 0 
 +  Positive for MSI 
 -  Negative for MSI 
 NI Non Informative with specified marker 
 
 
 Of the thirty-two samples analyzed, twenty-six were considered to be 
informative in this study.  Six (23.1%) of the twenty-six informative samples tested 
positive for MSI when compared to adjacent normal samples (Table 3.5).  Tumor 
samples that displayed additional shifted bands when compared to adjacent normal 
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tissue samples were considered an indication of instability in the microsatellite site and 
scored  positive (+).   
 
 
 1                2      3              4                5           6         7                8               9 
Figure 3.3 Representative examples of D10S208 Analysis. 
 
Audioradiograph of MSI test.  Lane 6 is a blank and was the negative control in this 
analysis with water instead of DNA template.  Lanes 1 is the positive control of normal 
DNA template for comparison to SSC tissue.  Lane 7 and 8 were positive for MSI and 
was characterized by the addition of an allele when compared to normal tissue samples. 
 
 
 The level of MSI detected in the SCC tissue using the D10S587 locus was not 
found to be a statistically significantly different from the adjacent normal tissue samples 
analyzed (p=0.395).  Thirteen adjacent normal and eighteen adjacent lichen sclerosis 
tissue samples were tested for MSI.  Twelve out of the thirteen adjacent normal samples 
tested negative (-) for MSI.  Representative examples of the analysis of MSI in the three 
tissue types are illustrated in figure 3.4. 
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Table 3.5 Assessment of MSI with D10S587 
Specimen Identifier D10S587 Specimen Identifier D10S587 
CW 3-3 SCC - CW 39-2 SCC + 
CW 5-1 SCC - CW 40-1 SCC - 
CW 12-4 SCC + CW 41-1 SCC - 
CW 16-2 SCC NI CW 41-8 SCC - 
CW 17-1 SCC - CW 43-1 SCC + 
CW 18-1 SCC - CW 44-2 SCC - 
CW 19-1 SCC - CW 47-2 SCC - 
CW 19-2 SCC NI CW 49-1 SCC - 
CW 23-1 SCC NI CW 50-1 SCC - 
CW 24-1 SCC NI CW 57-1 SCC - 
CW 25-1 SCC NI CW 61-6 SCC - 
CW 26-2 SCC + CW 63-1 SCC - 
CW 28-1 SCC - CW 64-3 SCC - 
CW 29-1 SCC + CW 70-3 SCC - 
CW 29-6 SCC + CW 80-2 SCC - 
CW 35-3 SCC NI CW 97-1 SCC - 
D10S208 Informative 
Cases 
MSI + % MSI 
SCC 26.0 6.0 23.1 
LS 17.0 1.0 5.9 
N 12.0 1.0 8.3 
 +  Positive for MSI 
 -  Negative for MSI 
 NI Non Informative with specified marker 
 
 
3.6 MSI-H and MSI-L 
Tumors occurring in humans that are exhibiting microsatellite instability high 
(MSI-H) is characterized by defective DNA mismatch repair genes (Morifugi et al., 
2003).    Disruption of the mismatch repair system in MSI-H cancers is most often 
caused by methylation of hMSH1 or hMSH2 (Cejka et al., 2003: Fleisher et al., 2000).  
Non-MSI-H cancers can either be classified as microsatellite stable (MSS) cancers or 
cancers with low-level microsatellite instability (MSI-L).  MSI-L cancers are based 
solely on frequency because they lack the definitive molecular and biological features  
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  1              2               3              4               5                6               7               8 
Figure 3.4: Representative examples of D10S587 Analysis. 
 
Audioradiograph of SCC Tissue tested for MSI.  Lanes 2 is the positive control of 
normal DNA template for comparison to SSC tissue.  Lane 1 was positive for MSI and 
was characterized by the addition of an allele when compared to normal tissue samples. 
 
 
observed in MSI-H cancers.  The studies reviewed have failed to reveal any significant 
difference in the pathological features between MSS and MSI-L cancers. 
As in previous studies, cases were considered to be MSI-H when two or more of 
the microsatellite loci displayed variations in the fragment pattern of the allele with the 
same tissue sample (Goel et al., 2003: Hartmann et al., 2002: Cruz  et al., 2000).  Cases 
were labeled MSI-L when the case was positive for MSI with one marker and MSS 
when all of the markers were negative for MSI.  The high frequency of MSI tumors 
(MSI-H), defined as tumors having instability in more than two markers, were detected 
in ten of the thirty-two (33%) SCC samples analyzed (Table 3.6).  The adjacent normal  
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Table 3.6: Assessment of MSI-H, MSI-L, and MSS in tissue samples 
Case Identifier Stability Case Identifier Stability 
CW 3-3 SCC MSI L CW 40-5 LS MSS 
CW 5-1 SCC MSI H CW 41-1 SCC MSI L 
CW 12-4 SCC MSI L CW 41-8 SCC MSI L 
CW 16-2 SCC MSI L CW 43-1 SCC MSI H 
CW 16-3 N MSS CW 44-1 N MSI L 
CW 17-1 SCC MSS CW 44-2 SCC MSI H 
CW 17-5 N MSS CW 44-4 LS MSI H 
CW 17-6 LS MSI L CW 45-4 N MSS 
CW 18-1 SCC MSS CW 46-6 LS MSS 
CW 18-5 N MSS CW 47-2 SCC MSI L 
CW 19-1 SCC MSS CW 47-3 LS MSS 
CW 19-2 SCC NI CW 49-1 SCC MSS 
CW 21-2 LS MSS CW 49-4 LS MSS 
CW 23-1 SCC MSI L CW 49-6 LS MSS 
CW 23-3 N MSS CW 49-7 N MSI L 
CW 24-1 SCC MSI L CW 50-1 SCC MSI H 
CW 25-1 SCC MSI L CW 50-5 LS MSS 
CW 25-4 LS MSS CW 52-2 N MSS 
CW 26-2 SCC MSI H CW 57-1 SCC MSI L 
CW 28-1 SCC MSI L CW 61-2 LS MSS 
CW 28-4 LS MSS CW 61-6 SCC MSI H 
CW 29-1 SCC MSI H CW 63-1 SCC MSI H 
CW 29-3 N MSS CW 64-3 SCC MSI L 
CW 29-5 LS MSS CW 70-1 LS MSS 
CW 29-6 SCC MSI H CW 70-3 SCC MSS 
CW 30-6 LS MSS CW 70-5 LS MSS 
CW 35-3 SCC NI CW 70-7 N MSS 
CW 39-1 N MSS CW 73-1 N MSI L 
CW 39-2 SCC MSI H CW 73-3 COND MSS 
CW 39-3 LS MSI H CW 80-2 SCC MSI L 
CW 40-1 SCC MSI L CW 91-5 LSC MSS 
CW 40-4 N MSS CW 97-1 SCC MSS 
 Stability Class  
Pathology MSI-H MSI-L MSS NI Total Cases 
Tested 
SCC 10 (33%) 14 (47%)  6 (20%) 2 (6%) 32 
LS 2 (11%) 1 (6%) 15 (83%) 0 (0%) 18 
Normal 0 (0%) 3 (15%) 10 (85%) 0 (0%) 13 
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tissue samples analyzed were either MSI-L or MSS.  Two of the adjacent LS were 
considered to be MSI-H (11%) and one adjacent LS tissue sample was considered to be 
MSI-L (6%) the other fifteen samples were considered to be MSS. 
3.7 Statistical Analysis 
Frequencies of allelic loss at individual loci were expressed as the number of 
cases scoring positive for MSI over the total number of cases informative at that locus.  
The Fisher’s exact test was used for the comparative analysis of the results (Appendix F 
G, H, and I).    A p value of equal to or less than 0.05 was considered to demonstrate the 
presence of a statistically significant difference between vulvar SCC and adjacent 
normal tissue samples (Table 3.7).  Loci that showed statistically significant differences 
between vulvar SCC and adjacent normal tissue samples were considered to be 
informative markers for MSI.   
 
Table 3.7:Statistical comparison between SCC and adjacent normal samples 
 
Primer SCC Normal P Value  P<0.05 
BAT-25 11.1 % 7.7 % 1.000 No 
BAT-26 56.7 % 10.0 % 0.013 Yes 
D10S208 37.9 % 0.0 % 0.009 Yes 





Most cancers arise as a result of the accumulation of genetic changes, which 
affect many chromosomes and genes.  Limited research has been done to examine MSI in 
tissues with squamous cell carcinoma and predisposing lesions such as lichen sclerosis.  
MSI has been seen in tissue associated with lung, colorectal, and other cancers.  The 
focus of this project was to determine if human vulvar SCC and adjacent LS display 
genomic instability in the form of MSI. 
The major objective of this study was to determine whether a panel of four 
markers could be associated with vulvar SCC.  It was found that three markers, BAT-26, 
D10S208, and D10S587, were considered informative in examining MSI in vulvar SCC.  
MSI was found in using all four loci, with BAT-26 being the most informative of the 
four.  A high level of MSI was found in 33% of the SCC tissue tested.  The progression 
from adjacent normal tissue to adjacent LS did not display a relative increase in MSI.  
Vulvar SCC tissue demonstrated the greatest levels of MSI and the MSI is a characteristic 
of genetic instability and the cancerous state.   
The results of the analysis of MSI in the adjacent normal and adjacent LS found 
that there were no significant differences between these two tissue types.   The adjacent 
normal and adjacent LS tissue tested indicated no significant difference in MSI and was 
considered to be MSS or MSI-L, with only two adjacent LS specimens considered to be 
MSI-H.  The difference between tumors with MSI-L and MSS is considered to be 
ambiguous and not well understood.  Several studies find that there is little pathological 
difference between these two classifications. 
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In colorectal carcinoma, high-frequency MSI tends to confer a considerable 
survival advantage over patients with cancers that are not associated MSI-H (Gryfe R et 
al., 2000).  Contrary to this statement, a National Cancer Institute workshop concluded 
that MSI had not yet been shown conclusively to be an independent predictor of survival 
(Dietmaier et al., 1999).  More research needs to be done to understand the effects MSI 
has on prognosis. 
A comparison of case specific results for each marker was analyzed and found to 
follow the accepted idea of instability through progression.   MSI in adjacent normal 
tissue and adjacent LS tissue was comparatively similar and statistically different than 
SCC samples.  BAT-26 was noted in the volgalgram in chapter one and was displayed in 
the progression to genomic instability characterized in early carcinoma.  The findings of 
the current study of MSI with vulvar SCC and adjacent LS correlate to Dr. Volgastiens 
work on progression of cancer and genomic instability.   
BAT-26 is associated with the hMSH2 tumor suppressor gene and is important in 
mismatch repair.  BAT-26 was considered to have the highest level of MSI and since 
MSI is a hallmark of mismatch repair problems, it can be assumed that there is a 
dysfunction in the mismatch repair genes.  Genomic instability pathways of 
carcinogenesis, characterized by mismatch repair defects and MSI, appear to play a role 
in the genesis of some vulvar SCC types, based on the high incidence of MSI in 
association with BAT-26. 
Further study of the production efficiency of the mismatch repair gene would be 
informative in association with present findings.   The next step would be to study the 
efficiency of the hMSH2, DMBT1 and c-Kit genes associated to the microsatellite 
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markers analyzed in this study.  The study should examine the difference in expression of 
these three genes in associated with MSI.  The SCC samples that display MSI and MSI-H 
and have not been effected by hyper-methylated inactivation or mutation in the gene that 
causes negative effects.   
A secondary study looking at the expression of associated genes would establish a 
direct relationship between MSI and progression of genetic instability within the tumor 
tissue.  Findings of this type of study can be correlated with prognosis and help to 
establish a connection to MSI status.   
Vulvar SCC has shown genetic instability in the form of MSI with BAT-26, 
D10S208, and D10S587.  Further study will need to be conducted to asses what this 
association indicates.  The direction the study should take that would be the most 
informative in linking MSI to effects, would be to look at the interaction between MSI 
and gene expression.  Since three loci have been associated with vulvar SCC and MSI, 
the expression efficiency of their associated genes would be a good starting point and the 
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PROTOCOL FOR PHENOL EXTRACTION 
 
This protocol is adapted from the Beginning Molecular Biology Laboratory 
Manual and from Bruce A. Roe, Department of Chemistry and Biochemistry, The 
University of Oklahoma, Norman, Oklahoma 73019 for the isolation and extraction of 
DNA.   
DNA Isolation 
1. Add 500 µl grinding buffer to each pencil eraser size tissue sample and vortex for at 
least 15 minutes. 
 
2. Decant solution and add 500 µl of lysing buffer and 8ul of proteinase K to each 
sample.  Incubate at 37ºC for at least 12 hours. 
 
3. Add 500 µl of phenol to each tube vortex, and centrifuge for 10 minutes. 
 
4 Transfer aqueous top solution (no interphase) a clean labeled tubes and add 500 µl of 
chlorophorm. Vortex and centrifuge for 10 minutes. 
 
5. Repeat step 4, then transfer aqueous top solution to clean labeled tubes. 
 
6. Add 2-3 µl of sodium acetate to each sample then add 1000 µl of cold 95% ethanol to 
each sample and age in -70ºC freezer for 15 minutes.  Centrifuge samples for 30 
minutes and retain just the DNA pellet. 
 
7. Add 700 µl of 70% ethanol to each sample and put in -70 freezer for 10 minutes then 
centrifuge for 10 minutes. 
 
8. Pour off ethanol and dry the pellets in a vacuum centrifuge. 
 
DNA Extraction 
1.  Add an equal volume of TE-saturated phenol to the DNA sample contained in a 1.5 ml 
micro centrifuge tube and vortex for 15-30 seconds. 
2.  Centrifuge the sample for 5 minutes at room temperature to separate the phases. 
3.  Remove about 90% of the upper, aqueous layer to a clean tube, carefully avoiding 
proteins at the aqueous: phenol interface. At this stage the aqueous phase can be 
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extracted a second time with an equal volume of 1:1 TE-saturated phenol: chloroform, 
centrifuged and removed to a clean tube as above but this additional extraction usually 
is not necessary if care is taken during the first phenol extraction. 
4.  Add an equal volume of water-saturated ether, vortex briefly, and centrifuge for 3 
minutes at room temperature. Remove and discard the upper, ether layer, taking care 
to remove phenol droplets at the ether: aqueous interface. Repeat the ether extraction. 
5.   Ethanol precipitate the DNA by adding 2.5-3 volumes of ethanol-acetate. 
  
Phenol extraction is a common technique used to purify a DNA sample.  
Typically, an equal volume of TE-saturated phenol is added to an aqueous DNA sample 
in a micro centrifuge  tube.  The mixture is vigorously vortexed, and then centrifuged to 
enact phase separation.  The upper, aqueous layer carefully is removed to a new tube, 
avoiding the phenol interface and then is subjected to two ether extractions to remove 
residual phenol.  An equal volume of water-saturated ether is added to the tube, the 
mixture is vortexed, and the tube is centrifuged to allow phase separation.  The upper, 
ether layer is removed and discarded, including phenol droplets at the interface.  After 


















PROTOCOL FOR ETHANOL PRECIPITATION 
 
This protocol is adapted from the Beginning Molecular Biology Laboratory 
Manual and from Bruce A. Roe, Department of Chemistry and Biochemistry, The 
University of Oklahoma, Norman, Oklahoma 73019 for the concentrating of DNA.   
1.  Add 2.5-3 volumes of 95% ethanol/0.12 M sodium acetate to the DNA sample 
contained in a 1.5 ml micro centrifuge tube, invert to mix, and incubate in an ice-
water bath for at least 10 minutes. It is possible to place the sample at -20°C 
overnight at this stage. 
2. Centrifuge at 12,000 rpm in a micro centrifuge for 15 min at 4°C, decant the 
supernatant, and drain inverted on a paper towel. 
3. Add 80% ethanol (corresponding to about two volume of the original sample), 
incubate at room temperature for 5-10 min and centrifuge again for 5 min, and decant 
and drain the tube, as above. 
4.  Place the tube in a vacuum centrifuge and dry the DNA pellet for about 5-10 min, or 
until dry. 
5.  Always dissolve dried DNA in 10 mM Tris-HCl, pH 7.6-8.0, 0.1 mM EDTA (termed 
10:0.1 TE buffer). 
6.  It is advisable to aliquot the DNA purified in large scale isolations (i.e. 100 µg or 
more) into several small (0.5 ml) micro centrifuge tubes for frozen storage because 
repeated freezing and thawing is not advisable. 
 
Typically, 2.5 - 3 µl of an ethanol/acetate solution is added to the DNA sample in a 
micro centrifuge tube, which is incubated at -20C overnight. To recover the precipitated 
DNA, the tube is centrifuged, the supernatant discarded, and the DNA pellet is rinsed 
with a more dilute ethanol solution. After a second centrifugation, the supernatant  again 





PROTOCOL FOR ENDLABELING WITH GAMMA 
1) Prepare a 0.7mL tube for each primer to be end- labeled and add the following: 
 a) 5 µl of Invariant primer dilution (25 pmol/ µl) 
 b) 1 µl of T4 Polnucleotide Kinase (New England Biolabs, Inc.) 
 c) 4 µl of NEB 10X PNK Buffer1 
 d) 32P ATP (>5000Ci/mmole) (14 day half- life) 
  Add (12 µl 32P ATP + 1 µl for each day past the assay date) (34 µl max) 
  Add dH2O to bring total reaction volume to 40 µl 
 
2) Incubate tubes at 37 oC (40-60 minutes) 
 
3) Add 2 µl of 0.5 mM ATP to force reaction and incubate at 37 oC for 4 minutes. 
 
4) Add 2 µl of 0.5 M EDTA to stop reaction 
 
5) Prepare G25 columns to purify end- labeled primers 
 
 a) Use 15 ml capped tubes for spinning columns. 
 
 b) Spin G25 tubes @ 2200 rpm, 4-5 minutes to drain the buffer, repeat 
 
 c) Join G25 columns to final collection tubes (labeled), in the 15 ml tubes. 
 
6) Recover 32P labeled primer 
 
 a) Pipette reaction mixture to center of column bed 
 
 b) Centrifuge 4-5 minutes @ 2200 rpm 
 
 c) Discard columns in the hot room radioactive waste bin 
 
 d) Save 15 ml capped tubes for re-use 
 
7) Quantitate radioactive incorporation using scintillation counter 
 
8) Place a 0.7 ml tube with 1 µl of labeled primer and push start. 
 





PROTOCOL FOR POLYMERASE CHAIN REACTION (PCR) 
 
 This protocol was designed to amplify MSI sites in target DNA sequences.  All of 
the solutions in this protocol are prepared in a cold block (0ºC), unless noted otherwise.   
HPLC grade water, obtained from Fisher Scientific, Fair Lawn, NJ, used in this protocol 
was passed through a 0.045 micron filter to ensure purity.    
Each sample was mixed in a 50 µl micro centrifuge tube and contained: 
  
 a) 200 ng of sample DNA 
 
 b) 2.5 µl of 10X PCR Buffer 
 
 c) 1.5 µl MgCl2 (25 mM Stock) 
 
 d) 1 µl of PCR forward and reverse primer mix (25pmol/µl Stock of each) 
 
 e) 2 µl of dNTP (10 mM each, deoxribonucleotide triphosphated dA, dC, dG, dT) 
 
 f) 0.2 µl Taq Gold DNA Polymerase (1 unit per reaction) 
 
 h) add pure water to 25 µl 
 
Thermal-Cycler is then programmed at: 
 




 96ºC for 1 minute (denaturation) 
 
 55ºC for 1 minute (annealing) 
 
 72ºC for 1 minute (polymerase extension) 
 
For 35 cycles then, 
 
 72ºC for 10 minutes (final extension) 
 









1) Prepare glass plates by cleaning with ethyl alcohol and large kimwipes 
 
2) Siliconize glass plates (internal surfaces) with 550-600 µl of Sigmacote. 
 
3) Prepare a 150 ml beaker with a stir bar and add (total volume is 70 ml): 
 
  a) 30.3 g of UltrapureTM urea (Sigma) 
 
  b) 30 ml of dionized water 
 
  c) 7.2 ml of autoclaved TBE 
 
  d) 11 ml of 19:1 Acrylamide 40 % (W/V): Bis (Amresco) 
 
4) Allow flask to stir on a plate set a #4 (a higher setting incorporates air) until urea is 
dissolved. 
 
5) After solution is thoroughly dissolved add following: 
 
  a) 500 µl of 10 % APS (Ammonium Persulfate) 
 
  b) 50 µl of TEMED (N,N,N’,N’-Tetra-methyl-ethyl-enediamine) 
 
6)  Place spacer strips on prepared glass plates and tape together.  
 
7) Add binder clamps to the sides of the glass plates to ensure a tight fit. 
 
8) Mixing the solution thoroughly, pour the gel into the prepared glass plates and allow 




















Data source: BAT-25 vs. Normal 
(P = 1.000) 
 
Subjects MSI  Stable    
Normal 1.000  12.000  Counts  
  1.300  11.700  Expected Counts  
  7.692  92.308  Row % 
  25.000  33.333  Column %  
  2.500  30.000  Total %  
 
 
     
SCC  3.000  24.000  Counts  
  2.700  24.300  Expected Counts  
  11.111  88.889  Row % 
  75.000  66.667  Column %  
  7.500  60.000  Total %  
 
 
The proportion of observations in the different categories which define the contingency 




























Data source: BAT-26 vs. Normal 
 
(P = 0.013) 
 
Subjects MSI  Stable    
Normal 1.000  9.000  Counts  
  4.500  5.500  Expected Counts  
  10.000  90.000  Row % 
  5.556  40.909  Column %  
  2.500  22.500  Total %  
 
 
     
SCC  17.000  13.000  Counts  
  13.500  16.500  Expected Counts  
  56.667  43.333  Row % 
  94.444  59.091  Column %  
  42.500  32.500  Total %  
 
 
The proportion of observations in the different categories which define the contingency 

























Data source: D10S208 vs. Normal 
(P = 0.009) 
 
Subjects MSI  Stable    
Normal 0.000  13.000  Counts  
  3.405  9.595  Expected Counts  
  0.000  100.000 Row % 
  0.000  41.935  Column %  
  0.000  30.952  Total %  
 
 
     
SCC  11.000  18.000  Counts  
  7.595  21.405  Expected Counts  
  37.931  62.069  Row % 
  100.000 58.065  Column %  
  26.190  42.857  Total %  
 
 
The proportion of observations in the different categories which define the contingency 



























Data source: D10S587 vs. Normal 
(P = 0.395) 
 
Subjects MSI  Stable    
Normal 1.000  11.000  Counts  
              2.211  9.789  Expected Counts  
  8.333  91.667  Row % 
  14.286  35.484  Column %  
  2.632  28.947  Total %  
 
 
     
SCC  6.000  20.000  Counts  
  4.789  21.211  Expected Counts  
  23.077  76.923  Row % 
  85.714  64.516  Column %  
  15.789  52.632  Total %  
 
 
The proportion of observations in the different categories which define the contingency 





















 Sidney Joseph Marlborough, III, was born on October 4, 1973 in a taxi crossing 
the Greater New Orleans Mississippi River Bridge, and life has been an uphill climb 
since.  He graduated eighth grade from Holy Name of Mary in Old Algiers on the west 
bank.  He then went on to San Diego for the next four years and finished high school at 
Orange Glen High School in Escondido, California.  His freshman year of college was 
completed at Louisiana State University in 1992.  After the grueling years of studying, 
working and dragon slaying (drinking, partying, and gaming), he finally graduated in 
1998 with a Bachelor of Science in environmental management systems. 
 Upon completion he spent three years of mind numbing hell at the state’s 
Department of Environmental Quality where he found out how far a man can go.  From 
this experience he ran to the nearest consulting company as well as back to school to 
begin a masters program under the world renowned tutelage  of Doctor Vince Wilson.  
Once starting this project he dove in, figuratively, and found out that genetics was not an 
exact science (who knew?).  Finally graduating from LSU with a Master of Science in 
environmental sciences (toxicology), he shall go on into the world and try and pay off the 
student loans and other bills.  He is joined in this effort by his plucky sidekick (wife) and 
mini me (daughter) adventuring onward fighting injustice and evil as well as looking for 
a good Chinese food.  We hear there is a great one at the end of the Universe, See You 
There.  
  
